本帖最后由 老马 于 2013-3-13 13:43 编辑 : @4 y5 S" @& y5 y, B/ z5 m
- M1 \# c' F" ]" f; O
健择（吉西他滨）+顺铂+阿瓦斯汀4 W8 @& }9 f7 l
Gemzar +Cisplatin + Avastin9 b( }9 i8 a, W; ^# R, y9 t( \
http://annonc.oxfordjournals.org/content/21/9/1804.full! w4 d) p; z# Q& c3 H4 \
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) $ _3 J1 M* @2 P2 i& L& H. r# F
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. . M/ I2 l7 f9 T5 f; Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. / o" F6 c- [6 o# @9 T, H( v
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 762)
, H- Q5 l7 K0 S) C# Q华为网盘附件：
, h+ ?: m7 U) [# T% B( j【华为网盘】ava.JPG* \/ q/ W7 l4 ~# T' F4 U& A
|
显身卡
